RS BioTherapeutics and NIAAA partner on RSBT-001 evaluation for IPF
The partnership is intended to study the anti-inflammatory and anti-fibrotic potential of the life sciences company’s RSBT-001 in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
30 Aug 23
The partnership is intended to study the anti-inflammatory and anti-fibrotic potential of the life sciences company’s RSBT-001 in…
30 Aug 23
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq® SC (atezolizumab) has been approved by the Medicines…
30 Aug 23
Celularity to provide research support for Regeneron’s targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy
30 Aug 23
This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021
29 Aug 23
Abcam, a UK-based provider of protein-based antibodies, reagents, biomarkers, and assays, will operate as a standalone company and…
29 Aug 23
The approval was based on the findings from the Phase 3 COMMANDS trial in which 58.5% of patients…
29 Aug 23
Mycamine is said to be a preferred treatment in hospitals and intensive care units around the world for…
29 Aug 23
The sNDA filing was based on the data from Cohort 1 of the late-stage THOR trial in which…
29 Aug 23
Upon completion of the transaction, Thorne will transition into a privately held entity, and its common stock shares…
29 Aug 23
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings,…